#### 506658151 05/12/2021

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

EPAS ID: PAT6704963

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
ARRANTA BIO FL, LLC	09/09/2020

#### **RECEIVING PARTY DATA**

Name:	OXIDIEN PHARMACEUTICALS, LLC	
Street Address:	747 SW 2ND AVENUE, SUITE 204, IMB57	
City:	GAINESVILLE	
State/Country:	FLORIDA	
Postal Code:	32601	

### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	13511834

#### **CORRESPONDENCE DATA**

Fax Number: (407)926-7720

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 407-926-7726

ktissue@savvyIPlaw.com Email:

Correspondent Name: WOLTER VAN DYKE DAVIS, PLLC

Address Line 1: 1900 SUMMIT TOWER BLVD, SUITE 140

Address Line 4: ORLANDO, FLORIDA 32810

ATTORNEY DOCKET NUMBER:	11922-003US
NAME OF SUBMITTER:	TIMOTHY H. VAN DYKE
SIGNATURE:	/Timothy H. Van Dyke/
DATE SIGNED:	05/12/2021

# **Total Attachments: 2**

source=Exhibit F. Non-EP\_ASGN\_toOxidien-final\_w. Appendix A -Arranta signed-hc signed#page1.tif source=Exhibit F. Non-EP\_ASGN\_toOxidien-final\_w. Appendix A -Arranta signed-hc signed#page2.tif

**PATENT** REEL: 056212 FRAME: 0327 506658151

## PATENT ASSIGNMENT

WHEREAS, Captozyme, Inc. of Gainesville, Florida has been converted to Arranta Bio FL, LLC (incorporated in Delaware, USA) with offices in Gainesville, Florida;

WHEREAS, for other good and valuable consideration of which receipt is acknowledged, Arranta Bio FL, LLC ("Assignor")

HEREBY sells and assigns to **Oxidien Pharmaceuticals, LLC** with offices in Gainesville, Florida, its successors and assigns ("Assignee") its entire right, title and interest to applications enumerated in Appendix A and inventions described therein, and any and all applications for patent and patents which may be applied for and granted therefrom in any and all countries, including all divisions, continuations, substitutes, renewals, reexaminations and reissues thereof and all other application for letters patent which are or have been filed for the inventions described and claimed in the United States, its territorial possessions, and all foreign countries and in all patents and extensions which may be granted therefrom.

In addition, to the extent needed to transfer valid patent rights in any given country, Assignor assign all rights to claim the benefit of priority resulting from the filing of the '805 App, '907 App, '927 App, '937 App and '976 App as so named in Appendix A, and authorize and request any official whose duty it is to issue patents, to issue any patent on said inventions and improvements resulting therefrom to Assignee and further agrees to: (a) cooperate with Assignee in the protection of the patent rights and prosecution and protection of foreign counterparts; (b) execute, verify, acknowledge and deliver all such further papers, including patent applications and instruments of transfer; and (c) perform such other acts as Assignee lawfully may request to obtain or maintain the Patent and any and all applications and registrations for the invention in any and all countries.

Digitally signed Lana by Lana Gladstein DocuSigned by: Gladstein Date: 2020.08.10 9/9/2020 Date: August 10, 2020 Date: Lana Gladstein Helena Cowley Chief Legal Officer & General Counsel Manager Arranta Bio FL, LLC. Oxidien Pharmaceuticals, Inc. (Assignor) (Assignee)

Ap	pendix	A
	P	

Application No.
Australian Patent Applicant No. 2010324830
Now Australian patent No. 2010324830
Canadian Patent Application No. 2,781,712
Chinese Patent Application No. 201080062401.X
Chinese Patent Application No. 201711280326.4
European Patent Application No. EP10833855.9
Japanese Patent Application No. 2012-541163
Now Japanese patent No. 5997610
PCT Application No. PCT/US2010/057805 ('805 App)
U.S. Application No. 61/281,907 ('907 App)
U.S. Application No. 61/395, 929 ('929 App)
U.S. Application No. 13/511,834
Now U.S. Patent No. 9,795,657
Australian Patent Application No. 2016244121
Canadian Patent Application No. 2,984,763
Chinese Patent Application No. 201680030901.2
Indian Patent Application No. 201717039146
Korean Patent Application No. 10-2017-7031741
PCT Application No. PCT/US2016/025937 ('937 App)
U.S. Patent Application No. 15/563,828
U.S. Provisional Patent Application No. 62/141,976 ('976 App)